Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.

Example Input: The coronavirus, which emerged in China late last year, has decimated global markets as it quickly moves around the world. It appeared poised for a spike in the United States, in part because of more testing to confirm cases. Florida late Sunday declared a public health emergency as it confirmed its first two cases. Trump administration officials worked Sunday to soothe nerves and calm fears that a global recession was looming, arguing that the public and media were over-reacting and saying that stocks would bounce back because the American economy was fundamentally strong. The total number of confirmed cases in the United States is more than 75 with two reported deaths, both in Washington state. Globally there have been more than 87,000 cases and nearly 3,000 deaths in 60 countries, according to the World Health Organization. In the United States, a cluster of cases is centered on a nursing home near Seattle. The Seattle and King County public health department confirmed late Sunday that a man in his 70s who was a resident of the LifeCare long-term care facility in Kirkland and had coronavirus had died the day before. On Saturday, the department had reported the first death of a coronavirus patient in the United States, a man in his 50s who was living in Kirkland - the same city where the nursing home is located. Six of the 10 confirmed coronavirus cases in Washington state have been residents or workers at LifeCare. State officials said an additional 27 residents of the nursing home and 25 staff members were reporting symptoms of the virus, which can be similar to that of the common flu. New York Governor Andrew Cuomo confirmed on Twitter his state's first coronavirus case, a woman in her 30s who caught the virus during a recent trip to Iran and was now in home quarantine. Cuomo did not say where the woman lived, but the New York Times reported she was in the Manhattan borough of New York City, citing state officials. "The patient has respiratory symptoms, but is not in serious condition and has been in a controlled situation since arriving in New York," Cuomo said. Stock markets plunged last week, with an index of global stocks setting its largest weekly fall since the 2008 financial crisis, and more than $5 trillion wiped off the value of stocks worldwide. A key energy conference in Houston that brings together oil ministers and energy firms was canceled on Sunday with the organizers of CERAWeek noting that border health checks were becoming more restrictive and companies had begun barring non-essential travel to protect workers. A world economy conference with Pope Francis due to take place in Italy later this month was also canceled. Trump said on Sunday that travelers to the United States from countries at high risk of coronavirus would be screened before boarding and on arrival, without specifying which countries. Delta Air Lines Inc said on Sunday it was suspending until May flights to Milan in northern Italy, where most of that country's coronavirus cases have been reported. Flights will continue to Rome. American Airlines Group Inc announced a similar move late on Saturday. The United States has 75,000 test kits for coronavirus and will expand that number "radically" in coming weeks, U.S. Health and Human Services Secretary Alex Azar told ABC's "This Week" on Sunday. Vice President Mike Pence, appointed last week to run the White House's coronavirus response, said the government had contracted 3M Co to produce an extra 35 million respiratory masks a month. He urged Americans not to buy the masks, which he said were only needed by healthcare workers. Honeywell International Inc is the other major U.S. mask producer. He also told Fox News that clinical trials of a coronavirus vaccine would start in six weeks but that a vaccine would likely not be available this season. Democrats, who will challenge Trump for the presidency in the Nov. 3 election, have criticized his administration for downplaying the crisis and not preparing for the disease to spread in the United States. Pence said Americans should brace for more cases but that the "vast majority" of those who contracted the disease would recover. "Other than in areas where there are individuals that have been infected with the coronavirus, people need to understand that for the average American, the risk does remain low. We're ready," Pence told NBC's "Meet the Press."
Example Output: Washington state confirms second U.S. coronavirus death; New York reports first case.

Example Input: Health workers were desperate to persuade him to get vaccinated for Ebola after a friend fell ill with the lethal and highly contagious disease. But within days, Nduhi was dead. His widow and their four young children were given his positive Ebola test result and a chilling warning from a team of health workers: "If you don't accept vaccination, you can prepare to die." Deep distrust along with political instability and deadly violence has severely undermined efforts by public health authorities in Congo to curb the outbreak by tracing and vaccinating those who may have come into contact with infected people. Health experts agree the experimental Ebola vaccine has saved multitudes in Congo. But after nearly a year and some 171,000 doses given, the epidemic shows few signs of waning. The virus has killed more than 1,700 people and has now arrived in the region's largest city, Goma. The World Health Organization last week declared the outbreak a global health emergency. During the 2014-16 Ebola epidemic in West Africa, which left more than 11,300 people dead, health workers could only dream of a vaccine with a 97.5 percent effectiveness rate that could improve the odds of survival even in those already infected. "We have it now and it's not the miracle we wanted it to be," said Dr. Joanne Liu, president of Doctors Without Borders. "The fact that we've used so much vaccine, and the epidemic hasn't stopped, that shows us that contact tracing is not great." WHO says as many as 90 percent of those eligible for vaccination have accepted it, but that figure only includes those who gave contact tracers enough information to be included on a list. The success rate excludes those who distrusted health workers and fled, or those who couldn't be found in the first place. Health workers have been using what is known as a ring vaccination strategy: The vaccine is first given to those who were in close contact with a sick person. Then a second so-called ring is created by giving the vaccine to those who were in contact with those people. Because of the difficulties in making that strategy work, some people didn't get vaccinated until they had already been infected with the virus, and they developed Ebola anyway. That increased doubts about the vaccine in communities where the public health campaigns led by outsiders already were viewed with suspicion and hostility. "The rumors were if you got vaccinated you would die," said Liboke Kakule Muhingi, a 43-year-old farmer in Mangina, where the epidemic began last August. His mother was among the first to die. Then, one by one, six of his sisters who had cared for their ailing mother were killed by Ebola. Kakule accepted the vaccine and made sure his wife and eight children got it, too. "If I hadn't, we'd all be dead," he said. In some cases, health teams have been unable to reach certain areas because of violence or rebel activity. Earlier this month, the head of the Congolese health ministry's response efforts in Beni was at one point unable to return from a field visit while the military battled ADF rebels, who are linked to the Islamic State. More often, though, contact lists have fallen apart simply because people have deliberately evaded health workers or did not understand they shouldn't travel after being exposed. A pastor who became the first confirmed case in Goma had apparently put down fake names at health checkpoints to avoid detection. He had been sickened in the town of Butembo and then took a bus while ill. WHO and the Congolese health ministry have now switched tactics and are offering the vaccine to anyone who wants it. With Ebola's arrival in Goma, a city of more than 2 million people, some wonder whether there will be enough of the vaccine if the outbreak continues. The vaccine's manufacturer, Merck, said it has 245,000 1-millileter doses on hand and that could rise to 900,000 over the next 18 months. The dose in Congo also has been reduced to 0.5 mL, effectively doubling the supply. "Whether or not the available doses are sufficient to fulfill the demands depends on the evolution of the outbreak, the access to the communities and the successful expansion of the production of additional doses by Merck in early 2020," WHO said. There is a second experimental vaccine, produced by Johnson & Johnson, but health officials in Congo have said it will not be used because it needs further testing and would cause too much confusion. It requires two doses given one month apart. It's unclear how long the Merck vaccine will protect people. Scientists know from early studies that it lasts for at least a year, but the epidemic is approaching that limit. The only study to report longer vaccine durability tracked only a small number of healthy volunteers in Geneva for two years. The new strategy of giving shots to anyone who wants them involves setting up "pop-up" sites in the neighborhoods most affected. Last week a vaccination team headed to the neighborhood in Beni where Nduhi's wife had stayed after he died. Outside the mud-brick home where his children still lived, a pickup truck full of plastic tables and chairs pulled over. Soon a tent was set up, and vaccination teams donned eye protection and yellow surgical gowns. Neighborhood children climbed the trees to watch. Baraka Kathembo Makasi, a 22-year-old motorbike taxi driver, brought his wife and two children with him. "At first I refused," he said, "but I started seeing people die and decided to go." ___ Associated Press writers Al-Hadji Kudra Maliro in Beni, Congo; Lauran Neergaard in Washington; Maria Cheng in London; and Jamey Keaten in Geneva contributed to this report.
Example Output: Ebola vaccine hampered by deep distrust in eastern Congo.

Example Input: Cost is not mentioned. The story is fairly specific about the fates of two groups of individualsmostly childrenwith epileptic seizures resistant toavailable medications. But since it uses only relative risk reduction figures to quantify the benefit, it doesn't go far enough to satisfy this criterion. The story says, for example, that "seizure frequency declined by an average 45 percent in all participants." Did they go from two seizures to one seizure per day or from 10 to 5? Providing the absolute numbers would have clarified the size of the benefit. The subheadline declares that "drug interactions remain a concern," and story includes reference to a study that found cannabidiol to interact "badly" with anti-seizure medications currently approved for epilepsy treatment. It later specifies the drugs that may be affected. We think this nod in the direction of harms is sufficient for a Satisfactory rating, although we're concerned that the story mentions no other side effects from the treatment. A news release noted that "Adverse events occurred in more than 10 percent of participants with the most common being somnolence, diarrhea and fatigue and led to discontinuation in 4 percent of patients." The story makes an early point that neither of the studies that received most of the attention was blinded; that is, both patients and scientists were aware of the procedures. The story also prominently reflects the views of an independent researcher who reminds readers that (1) placebo rates can be quite high and (2) the field won't know the "real" effects until well-designed clinical studies are conducted. Children whose epileptic seizures are not controlled by current drugs have few options. This is a real problem. There was no disease (or pot) mongering. Although the story does make clear the distinction between researchers involved in the studies discussed and those not involved, there is no mention of funding. Who funded the study is a very important question. It would also be important to know if any of the researchers involved/quoted were consultants/paid by this company. A news release issued in advance of the American Epilepsy Society meeting, where these studies were scheduled to be presented, notes that the medicine used (called Epidiolex) and was supplied by manufacturer GW Pharmaceutical. That information didn't make it into the story. The interest in marijuana constituents as possible treatments arose because existing alternativesanti-seizure drugsdo not work with some patients. So a premise of this story is that existing alternatives are unsuccessful in this group of paitents. One of the study investigators makesit clear that federal approval for the drug could take up to five years. However, the story also notes that some activist families have already begun using cannabidiol oils "that are made artisanally." Since cannabis has been used for the treatment of seizures for centuries, it's curious why the researchers didn't test the compound in a better designed trial (randomized, blinded and placebo controlled). The public and patients are still left with the question of whether this works. But the story does briefly mention previous studies that have looked at cannibidiol in adults, so the story gets a pass here. The story reflects some enterprise reporting independent of the news release from the American Epilepsy Society; for example, the reporter solicited information about the study's validity from an independent researcher.
Example Output:
Marijuana Chemical Shows Promise for Hard-to-Treat Epilepsy in Kids